On July 3, Peijia Medical hosted its 2026 Corporate Open Day under the theme “Building Momentum for Breakthroughs,” highlighting the Company’s latest progress in R&D, commercialization and globalization. Following years of sustained investment, the Company has established a comprehensive structural heart disease pipeline covering aortic stenosis, aortic regurgitation, and mitral and tricuspid valve diseases, as well as a neurointerventional portfolio spanning hemorrhagic stroke, ischemic stroke and access devices. Its accumulated R&D and commercialization capabilities are now entering a period of accelerated realization.

Commercially, the Company’s core sales network has achieved broad nationwide coverage. Its TAVR business maintains a leading market position, with TaurusTrio® rapidly gaining adoption and expanding the aortic regurgitation market. The neurointerventional portfolio also continues to grow, with improving profitability. Meanwhile, multiple innovative products in mitral and tricuspid valve therapies, TAVR procedural assistance and lithotripsy treatment for valvular calcification are making steady progress. The Company is also advancing overseas clinical and regulatory activities for multiple core products. With innovation increasingly translating into commercial results and its international footprint expanding, Peijia Medical is entering a new stage of scaled innovation and high-quality growth.

For more information, please visit:  https://mp.weixin.qq.com/s/gteKrDc4Kig458_0nSdsFw